PURPOSE:Prasugrel is a novel thienopyridine prodrug metabolised to an active metabolite that binds irreversibly to the platelet P2Y(12) receptor and inhibits adenosine diphosphate (ADP)-induced platelet aggregation. We compared prasugrel pharmacokinetics, pharmacodynamics, and tolerability in healthy Chinese, Japanese, Korean and Caucasian subjects. METHODS: In an open-label, single-centre, parallel-design study, 89 healthy subjects (25 Chinese, 20 Japanese, 22 Korean and 22 Caucasian) aged 20-65 years were given a prasugrel 60-mg loading dose (LD) followed by daily 10-mg maintenance doses (MD) for 7 days and then 5-mg MD for 10 days. Plasma concentrations of prasugrel's active metabolite and inhibition of ADP-induced platelet aggregation (IPA) were determined. RESULTS:Mean exposure to prasugrel's active metabolite in all treatment regimens was higher in each of the Asian groups than in the Caucasian group, although there was considerable overlap between individual exposure estimates in Asians and Caucasians. The mean IPA was also higher in Asians than in Caucasians following a prasugrel 60-mg LD, although the difference did not consistently achieve statistical significance. Prasugrel 10-mg or 5-mg MD produced statistically significantly higher IPA in each Asian group compared with that in the Caucasians. Prasugrel was well tolerated during the LD and MD regimens by all groups. CONCLUSIONS: Mean exposure to the prasugrel active metabolite following prasugrel 60-mg LD and during daily 10-mg or 5-mg MD was higher in each of the Asian groups than in the Caucasian group, which resulted in greater platelet inhibition.
RCT Entities:
PURPOSE:Prasugrel is a novel thienopyridine prodrug metabolised to an active metabolite that binds irreversibly to the platelet P2Y(12) receptor and inhibits adenosine diphosphate (ADP)-induced platelet aggregation. We compared prasugrel pharmacokinetics, pharmacodynamics, and tolerability in healthy Chinese, Japanese, Korean and Caucasian subjects. METHODS: In an open-label, single-centre, parallel-design study, 89 healthy subjects (25 Chinese, 20 Japanese, 22 Korean and 22 Caucasian) aged 20-65 years were given a prasugrel 60-mg loading dose (LD) followed by daily 10-mg maintenance doses (MD) for 7 days and then 5-mg MD for 10 days. Plasma concentrations of prasugrel's active metabolite and inhibition of ADP-induced platelet aggregation (IPA) were determined. RESULTS: Mean exposure to prasugrel's active metabolite in all treatment regimens was higher in each of the Asian groups than in the Caucasian group, although there was considerable overlap between individual exposure estimates in Asians and Caucasians. The mean IPA was also higher in Asians than in Caucasians following a prasugrel 60-mg LD, although the difference did not consistently achieve statistical significance. Prasugrel 10-mg or 5-mg MD produced statistically significantly higher IPA in each Asian group compared with that in the Caucasians. Prasugrel was well tolerated during the LD and MD regimens by all groups. CONCLUSIONS: Mean exposure to the prasugrel active metabolite following prasugrel 60-mg LD and during daily 10-mg or 5-mg MD was higher in each of the Asian groups than in the Caucasian group, which resulted in greater platelet inhibition.
Authors: Jessica L Fayer Rehmel; James A Eckstein; Nagy A Farid; John B Heim; Steve C Kasper; Atsushi Kurihara; Steven A Wrighton; Barbara J Ring Journal: Drug Metab Dispos Date: 2006-01-13 Impact factor: 3.922
Authors: John T Brandt; Christopher D Payne; Stephen D Wiviott; Govinda Weerakkody; Nagy A Farid; David S Small; Joseph A Jakubowski; Hideo Naganuma; Kenneth J Winters Journal: Am Heart J Date: 2007-01 Impact factor: 4.749
Authors: Nagy A Farid; Richard L Smith; Todd A Gillespie; T James Rash; Patrick E Blair; Atsushi Kurihara; Mark J Goldberg Journal: Drug Metab Dispos Date: 2007-04-02 Impact factor: 3.922
Authors: Eric T Williams; Karen O Jones; G Douglas Ponsler; Shane M Lowery; Everett J Perkins; Steven A Wrighton; Kenneth J Ruterbories; Miho Kazui; Nagy A Farid Journal: Drug Metab Dispos Date: 2008-03-27 Impact factor: 3.922
Authors: J T Brandt; S L Close; S J Iturria; C D Payne; N A Farid; C S Ernest; D R Lachno; D Salazar; K J Winters Journal: J Thromb Haemost Date: 2007-09-26 Impact factor: 5.824
Authors: C Steven Ernest; David S Small; Shashank Rohatagi; Daniel E Salazar; Lars Wallentin; Kenneth J Winters; Rebecca E Wrishko Journal: J Pharmacokinet Pharmacodyn Date: 2008-11-21 Impact factor: 2.745
Authors: David S Small; Nagy A Farid; Christopher D Payne; Christopher S Konkoy; Joseph A Jakubowski; Kenneth J Winters; Daniel E Salazar Journal: Clin Pharmacokinet Date: 2010-12 Impact factor: 6.447
Authors: Joseph A Jakubowski; Jeffrey S Riesmeyer; Sandra L Close; Amy G Leishman; David Erlinge Journal: Cardiovasc Ther Date: 2011-02-17 Impact factor: 3.023